



**UNIVERSIDADE FEDERAL DE SERGIPE**  
**CENTRO DE CIÊNCIAS BIOLÓGICAS E DA SAÚDE**  
**DEPARTAMENTO DE FARMÁCIA**

**RAFAELLA DE OLIVEIRA SANTOS SILVA**

**AVALIAÇÃO DE INDICADORES DE ESTRUTURA EM UM SERVIÇO**  
**DE REVISÃO DA FARMACOTERAPIA**

**São Cristóvão, SE**

**Dezembro de 2014**

**UNIVERSIDADE FEDERAL DE SERGIPE**  
**CENTRO DE CIÊNCIAS BIOLÓGICAS E DA SAÚDE**  
**DEPARTAMENTO DE FARMÁCIA**

**RAFAELLA DE OLIVEIRA SANTOS SILVA**

**AVALIAÇÃO DE INDICADORES DE ESTRUTURA EM UM SERVIÇO  
DE REVISÃO DA FARMACOTERAPIA**

Monografia apresentada como exigência  
para obtenção do título de **Bacharel em  
Farmácia.**

Orientador: Prof. Dr. Divaldo Pereira de Lyra Jr.

**São Cristóvão, SE**

**Dezembro de 2014**

## RESUMO

SILVA, R.O.S. **AVALIAÇÃO DE INDICADORES DE ESTRUTURA EM UM SERVIÇO DE REVISÃO DA FARMACOTERAPIA.** Trabalho de Monografia do curso de Farmácia da Universidade Federal de Sergipe, 2014.

Este estudo avalia indicadores de estrutura empregados na implantação do Serviço de Revisão da Farmacoterapia. Foi realizada uma pesquisa de desenvolvimento metodológico de março de 2012 a março de 2013, no Serviço de Revisão da Farmacoterapia do ambulatório-escola, de um Hospital Universitário no Nordeste do Brasil, em duas etapas consecutivas. A primeira etapa consistiu de uma busca na literatura sobre indicadores de estrutura para Serviços de Revisão da Farmacoterapia. Na segunda etapa foi feita a avaliação por meio dos indicadores reunidos na etapa anterior. Reunimos 28 indicadores de estrutura necessários para avaliar outros Serviços de Revisão da Farmacoterapia que foram divididos em cinco categorias: instalações físicas, recursos humanos, recursos materiais, documentação e financiamento. O Serviço de Revisão da Farmacoterapia analisado atendeu a maioria dos indicadores sugeridos pela literatura.

**Palavras-chave:** revisão da farmacoterapia; avaliação de qualidade de serviços; indicadores de estrutura

## **ABSTRACT**

**SILVA, R.O.S. EVALUATION OF A STRUCTURAL INDICATORS IN A MEDICATION REVIEW SERVICE.** Monograph Pharmacy Course at the Federal University of Sergipe, 2014.

This study evaluates structure indicators used in the implantation of the Medication Review Service. Developmental research methodological was carried out from March 2012 to March 2013, at the Medication Review Service of the school-based outpatient clinic of the University Hospital in Northeastern Brazil, in two consecutive steps. The first step consisted on a searching in the literature about structure indicators for Medication Review Service. On the second step was done the evaluation through the indicators gathered in the previous step. We gathered 28 structure indicators needed to assess other Medication Review Services that were divided into five categories: physical areas, human resources, material resources, documentation and funding. The Medication Review Service analyzed attended most indicators suggested by the literature.

**Keywords:** medication review; quality assurance (health care); structure indicators

## SUMÁRIO

INTRODUÇÃO.....	2
REFERÊNCIAS BIBLIOGRÁFICAS.....	4
ARTIGO.....	9
INTRODUCTION .....	12
METHODS.....	13
RESULTS.....	14
Structural indicators for the Medication Review service .....	14
Table 1. Structural indicators for clinical pharmacy services.....	15
Evaluation of the Medication Review service of a school-based outpatient clinic .....	19
DISCUSSION.....	20
CONCLUSION.....	24
ACKNOWLEDGMENTS .....	25
REFERENCES .....	26
RESEARCH HIGHLIGHTS.....	32
AUTHOR DECLARATION.....	33
HEALTH & PLACE - <i>Guide for authors</i> .....	34



## INTRODUÇÃO

A crescente morbimortalidade relacionada aos medicamentos é considerada um problema de saúde pública relevante em vários países do mundo, visto que o uso simultâneo de vários medicamentos tem se tornado uma ferramenta comum na prática clínica (Galato et al., 2010; Manasse Jr. e Thompson, 2005). Em consequência, os custos com a morbimortalidade relacionada à farmacoterapia nos Estados Unidos foram estimados em US\$ 300 bilhões de dólares (Center for Disease Control and Prevention, 2014; Rottenkolber et al., 2011). No mesmo país, os gastos provocados por problemas relacionados aos medicamentos (PRMs) foram duas vezes maiores que os gastos com os próprios medicamentos (Baker, 2004; Ernst e Grizzle, 2001).

Diante do exposto, a Organização Mundial de Saúde (OMS) (2002) estabeleceu como seu grande desafio para a década de 2010 a promoção e melhora na racionalidade do uso de medicamentos. Assim, OMS tem destacado que o papel do farmacêutico pode ser determinante para a prevenção de erros de medicação e promoção do uso racional de medicamentos, no que concerne às orientações dos pacientes nos diversos cenários de prática como hospitais, farmácias comunitárias e ambulatórios (World Health Organization, 1994; World Health Organization, 1998).

Nessa perspectiva, estudos demonstram que o aumento das consultas e outros serviços farmacêuticos em ambientes ambulatoriais proporcionam a oportunidade para otimizar o estado de saúde dos pacientes, como o seguimento farmacoterapêutico (Hirsch et al., 2014; Molino et al., 2014; Wei et al., 2014) e a Revisão da Farmacoterapia (Goh et al., 2014; Lenander et al., 2014). Este último serviço, foi definido inicialmente como a avaliação crítica e estruturada dos medicamentos do paciente com o objetivo de alcançar um comum acordo sobre sua farmacoterapia, otimizando o tratamento, diminuindo os problemas relacionados a medicamentos (PRMs) e os gastos dos sistemas de saúde (Shaw et al., 2002).

Na prática Clínica, a Revisão da Farmacoterapia vem trazendo diversos resultados clínicos, econômicos e humanísticos (López et al., 2012; Patterson et al., 2011; Riley, 2013). Em uma revisão sistemática com 54 estudos, Hatah et al. (2014) concluíram que a Revisão da Farmacoterapia teve impacto significativamente positivo sobre os resultados dos pacientes, como redução dos níveis pressóricos, níveis de

LDL (lipoproteína de baixa densidade), taxas de hospitalizações e PRMs, além de aumentar a adesão a farmacoterapia. Embora este serviço seja desenvolvido em vários países (Patterson et al., 2011; Leikola, 2012; Salgado et al., 2012) e, em alguns destes, com respaldo dos sistemas de saúde (Pharmaceutical Services Negotiating Committee, 2013; Pharmaceutical Society of Australia, 2011), as publicações sobre serviços farmacêuticos que se autodenominem como um serviço de Revisão da Farmacoterapia na América Latina são incipientes.

Neste cenário faz mais de uma década que a avaliação da qualidade dos serviços de cuidados vem ganhando força na maioria dos sistemas de saúde (Morris et al., 2002). Isso é explicado principalmente pelos prejuízos gerados pela morbimortalidade relacionada a medicamentos e a nova conjuntura dos sistemas de saúde em fornecer incentivos financeiros aos prestadores de cuidados (McBane et al., 2011). Assim, a nova tendência das agências de saúde é exigir dos prestadores de cuidados o mais alto grau de qualidade dos serviços de saúde ao menor custo possível (Mainz, 2003).

Um dos primeiros autores a estudar a avaliação da qualidade dos serviços de saúde foi Avedis Donabedian (1966). Segundo o mesmo para a qualidade em saúde, pode ser avaliada sob tríade estrutura, processo e resultado (Modelo SPO). A estrutura corresponde aos recursos físicos, humanos, materiais, instrumentos normativos e administrativos utilizados, assim como as fontes de financiamento. O processo, por sua vez, diz respeito às interações e procedimentos envolvendo profissionais de saúde e pacientes, enquanto que os resultados (*outcomes*) se referem à alteração no estado de saúde atribuível à intervenção em saúde (Donabedian, 1966, 1978).

Embora desde a década de 1970 sejam utilizados modelos para a avaliação da qualidade de serviços farmacêuticos (Mikael et al., 1975). No Brasil, estudos com foco no planejamento, monitorização e avaliação de serviços clínicos farmacêuticos, como a revisão da farmacoterapia são escassos. Portanto, é necessário que mais investigações sejam realizadas a fim de implantar, avaliar e difundir serviços clínicos que garantam a qualidade do cuidado e a segurança do paciente.

Diante do exposto, este estudo fez parte da Dissertação de Mestrado em Ciências Farmacêuticas da Universidade Federal de Sergipe de Genival Araújo dos Santos Júnior, intitulado: “Indicadores de estrutura e de processo em Serviços de



Revisão da Farmacoterapia”. O estudo será apresentado em forma de artigo com o título de: “**Evaluation of a structural indicators in a Medication Review Service**”. Este estudo será submetido à *Health & Place – an International Journal*, que possui qualis A2 e fator de impacto 2,435.

## REFERÊNCIAS BIBLIOGRÁFICAS

Baker, G.R., Norton, P.G., Flintoft, V., Blais, R., Brown, A., Cox, J., Etchells, E., Ghali, W.A., Hébert, P., Majumdar, S.R., O'Beirne, M., Palacios-Derflinger, L., Reid, R.J., Sheps, S., Tamblyn, R., 2004. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. *Canadian Medical Association Journal* 170(11), 1678–1686.

Donabedian, A., 1966. Evaluating the quality of medical care. *Milbank Memorial Fund Quarterly* 44, 166-206.

Donabedian, A., 1978. The quality of medical care. *Science* 200(4344), 856-864.

Ernst, F.R., Grizzle, A.J., 2001. Drug-related morbidity and mortality: Updating the cost of illness model. *Journal of American Pharmacists Association* 41(2), 192-199.

Galato D., Silva E.S., Tiburcio, L.S., 2010. Estudo de utilização de medicamentos em idosos residentes em uma cidade do sul de Santa Catarina (Brasil): um olhar sobre a polimedicação. *Revista Ciência & Saúde Coletiva* 15(6), 2899-2905.

Hatah, E., Braund, R., Tordoff, J., Duffull, S.B., 2014. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. *British Journal of Clinical Pharmacology* 77(1), 102–115.

Hirsch, J.D, Steers, N., Adler, D.S., Kuo, G.M., Morello, C.M., Lang, M., Singh, R.F., Wood, Y., Kaplan, R.M., Mangione, C.M., 2014. Primary Care–based, Pharmacist–physician Collaborative Medication-therapy Management of Hypertension: A Randomized, Pragmatic Trial. *Clinical Therapeutics* 36(9), 1244–1254.

Goh, B.Q., Tay, A.H.P., Khoo, R.S.Y., Goh, B.K., Lo, P.F.L., Lim, C.J.F., 2014. Effectiveness of Medication Review in Improving Medication Knowledge and Adherence in Primary Care Patients (Online). *Proceedings of Singapore Healthcare* 23(2) (acessado).

Leikola, S., 2012. Development and application of comprehensive medication review procedure to community-dwelling elderly. Tese de Doutorado, Universidade de Helsink, Helsink.

Lenander, C., Elfsson, B., Danielsson, B., Midlöv, P., Hasselström, J., 2014. Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. *Scandinavian Journal of Primary Health Care* (2014) <<http://dx.doi.org/10.3109/02813432.2014.972062>> (Online First).

López T.M., Camacho, J.C.D., Morgado, D.P., Camacho, M.O.C., Serna, J.C.M., Rubio, S.L., 2012. Revisión de la medicación en ancianos polimedicados en riesgo vascular: ensayo aleatorizado y controlado. *Atención Primaria* 44(8), 453-462.

Manasse Jr, H.R., Thompson K.K, 2005. Medication safety as problem in public policy. In: Conner, C.M., Floge, B. (Eds), *Medication safety: a guide for health care facilities*. ASHP, Bethesda, pp.1-15.

McBane, S., Trewet, C.B., Havican, S.M., Kiser, K., Klingel, C., Riche, D.M., Sease, J.M., Nau, D.P., Zillich A.J., 2011. Tenets for developing quality measures for ambulatory clinical pharmacy services. *Pharmacotherapy* 31(7), 115-134.

Mikeal, R.L., Brown, T.R., Lazarus, H.L., Vinson, M.C., 1975. Quality of pharmaceutical care in hospitals. *American Journal of Health-System Pharmacy* 32(6), 567-574.

Molino, C.G.R.C., Carnevale, R.C., Rodrigues A.T., Visacri, M.B., Moriel, P., Mazzola, P.G., 2014. Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection. *Therapeutics and Clinical Risk Management* 10, 631–639.

Morris, C.J., Cantrill, J.A., Hepler, C.D., Noyce, P.R., 2002. Preventing drug-related morbidity-determining valid indicators. *International Journal for Quality in Health Care* 14(3), 183-98.

Organización Mundial de La Salud, 2002. Perspectivas políticas de la OMS sobre medicamentos [Online]. Promoción del uso racional de medicamentos: componentes centrales. Organización Mundial de La Salud, Geneva, September 05, 2002. URL: <<http://www.who.int/medicinedocs/collect/medicinedocs/pdf/s4874s/s4874s.pdf>> (acessado 08.04.13).

Patterson, S.M., Hughes, C.M., Cardwell, C., Lapane, K.L., Murray, A.M., Crealey, G.E., 2011. A cluster randomized controlled trial of an adapted U.S. model of pharmaceutical care for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study): a cost-effectiveness analysis. *Journal of the American Geriatrics Society* 59(4), 586-593.

Pharmaceutical Services Negotiating Committee, 2013. Guidance on the medicines use review service [Online]. NHS Employers, London, October, 2013. URL: <<http://www.nhsemployers.org/~media/Employers/Documents/Primary%20care%20contracts/Pharmacy/MUR%20Guidance.pdf>> (acessado 29.11.14).

Pharmaceutical Society of Australia, 2011. Guidelines for pharmacists providing Home Medicines Review (HMR) services. PSA, Canberra.

Riley, K., 2013. Enhanced medication management services in the community: A win-win proposal from an economic, clinical and humanistic perspective. *Canadian Pharmacists Association* 146(3), 162-168.

Rottenkolber, D., Schmiedl, S., Rottenkolber, M., Farker, K., Saljé, K., Mueller, S., Hippus, M., Thuermann, P.A., Hasford, J., 2011. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. *Pharmacoepidemiology and Drug Safety* 20(6), 626-634.

Salgado, T.M., Moles, R., Benrimoj, S.I., Fernandez-Llimos, F., 2012. Exploring the role of renal pharmacists in outpatient dialysis centres: a qualitative study. *International Journal of Clinical Pharmacy* 34(4), 569-578.

Shaw, J., Seal, R., Pilling, M., 2002. Task force on medicines partnership and the national collaborative medicines management services programme. Room for review - a guide to medication review: the agenda for patients, practitioners and managers. Pharmaceutical Press, Wallingford.

Wei, L., Yang, X., Li, J., Liu, L., Luo, H., Zheng, Z., Wei, Y., 2014. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study. *Journal of Thoracic Disease* 6(6), 656–662.

World Health Organization, 1994. The Role of the Pharmacist in the Health Care System [Online]. WHO, New Delhi, December 16, 1988 and Tokyo, September 3, 1993. URL: <<http://apps.who.int/medicinedocs/en/d/Jh2995e/>> (acessado 14.04.13).

World Health Organization, 1998. The role of the pharmacist in self-care and self-medication. Report of the 4<sup>th</sup> Consultative Group on the Role of the Pharmacist. WHO, Hague.



## **Evaluation of a structural indicators in a Medication Review Service**

### **Rafaella de Oliveira Santos Silva**

Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

**Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil.**

**E-mail:** rafaellaa\_oliveira@hotmail.com/ lepfs.ufs@gmail.com

**Phone:** +557996077258

### **Genival Araújo dos Santos Júnior**

Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

Laboratory Pharmaceutical Testing and Toxicity (LEFT), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

**Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil.**

**E-mail:** farm.genival@gmail.com/ lepfs.ufs@gmail.com

**Phone:** +557999482287

### **Carina Carvalho Silvestre**

Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

**Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil.**

**E-mail:** caryna\_@hotmail.com/ lepfs.ufs@gmail.com

**Phone:** +557988369005

### **Tatiane Cristina Marques**

Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

**Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil.**

**E-mail:** tatianecm@hotmail.com/ lepfs.ufs@gmail.com

**Phone:** +557991655141

**Francilene Amaral da Silva**

Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

Laboratory Pharmaceutical Testing and Toxicity (LEFT), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

**Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil.**

**E-mail:** farmsilva@hotmail.com/ lepfs.ufs@gmail.com

**Phone:** +557988523213

**Divaldo Pereira de Lyra Júnior**

Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, São Cristóvão, SE, Brazil

**Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil.**

**E-mail:** lyra\_jr@hotmail.com/ lepfs.ufs@gmail.com

**Phone:** +557991925577

**Corresponding author: DP Lyra Jr. Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Address: Cidade Universitária “Prof. José Aloísio Campos”, Jardim Rosa Elze, São Cristóvão, CEP: 49100-000, Brazil. Phone/Fax: +557921056319. E-mail: lepfs.ufs@gmail.com.**



## INTRODUCTION

In last three decades, clinical services established with pharmacists' knowledge and skills have encouraged the training of health care professionals in the selection and monitoring of pharmacotherapy in practice scenarios, such as hospitals, community pharmacies, and ambulatory care clinics (Roberts et al., 2008; World Health Organization, 1994; World Health Organization, 1998). Among clinical pharmaceutical practices that focus on patients and help improve clinical, humanistic, and economic outcomes, Medication Review stands out (Doucette et al., 2009; El-Ibiary et al., 2008; Hatah et al., 2014; Murray et al., 2007; Planas et al., 2009).

Initially, Medication Review was defined as the careful analysis of medications used by patients to optimize their treatment, decrease drug related problems (DRPs), and decrease health system costs (Hatah et al., 2014; Shaw et al., 2002). Recently, Leikola (2012) confirmed that the main benefit of Medication Review is the improvement of outpatient therapeutic regimens.

In the United States, the expansion of these services started ten years ago and led patients and health plans to require the assessment of outpatient pharmaceutical care, such as Medication Review, focusing on cost-benefit ratio (Mainz, 2003). It is important to emphasize that quality assessment guarantees health care and health services management. Therefore, it is necessary to measure the efforts of institutions, the quality of health services provided, and their utility and social relevance (Adami, Maranhão, 1995; Carayon et al., 2014).

In this scenario, the model "structure-process-outcome" has been used to identify and associate processes developed by pharmacists and patient outcomes (Farris, Kirking, 1993; Nau, 2009). According to Donabedian (1966, 1978), structural indicators correspond to physical, human, and material resources regulatory and administrative instruments used, as well as funding sources. Process indicators, in turn, refer to interactions and procedures that involve health care professionals and patients, while the outcomes are measured by changes in health status that occur as a result of health care intervention.

Although these concepts are widely used, healthcare professionals, including pharmacists, have not assimilated the integrated concept of quality improvement in the clinical context (Bruchet, Loewen, 2011; Carayon et al., 2014). Consequently,

McBane et al. (2011) report the existence of few measures to assess the quality of different care services provided by pharmacists, including Medication Review.

In Brazil, for instance, there is no framework of standardized procedures, processes, or workflows to assess the quality of these services. Moreover, in this country, studies to address the quality of pharmaceutical services, such as Medication Review, still need to be performed. Therefore, further investigations would be required to optimize the quality of review services and health outcomes.

Considering this, the aim of this study was to assess structural indicators for the implementation of the Medication Review service in a school-based ambulatory care clinic of the University Hospital in Northeastern Brazil.

## **METHODS**

Developmental research methodological was carried out from March 2012 to March 2013, at the Medication Review Service of the school-based outpatient clinic of the University Hospital in Northeastern Brazil. The evaluation of pharmaceutical services was based on the model proposed by Donabedian (1988), focused on structure. Due to the lack of instruments to assess structural indicators for Medication Review, this study was divided into two consecutive phases.

The first phase consisted in finding and defining structural indicators of pharmaceutical services that could be properly adapted to Medication Review in outpatient clinics. Therefore, two international guidelines were selected: 1) “*Guidelines for pharmacists providing Home Medicines Review (HMR) services*” developed by the Pharmaceutical Society of Australia (2011); and 2) “*Minimum Standard for Pharmaceutical Services in Ambulatory Care*” proposed by the American Society of Health-System Pharmacists (ASHP) (1999). Moreover, six national research studies (Aguilar et al., 2013; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005; Rios et al., 2013; Silva, 2003) served as theoretical references to define the indicators that would then be analyzed.

The two international guidelines aimed to assess pharmaceutical services. On the other hand, the selected Brazilian studies addressed structural indicators for community or outpatient pharmacies with or without clinical pharmacy services. Hence, two pharmacists-investigators (G.A.S.J. and C.C.S.) selected, compiled, and

adapted structural indicators for this study, according to the theoretical framework proposed by Donabedian (1980). The degree of agreement between the two pharmacists was calculated using the *Kappa* index, which may vary from 0 to 1. The closer to 1 the index is, the higher is the agreement between the evaluators. For different responses, a third pharmacist (T.C.M.) was consulted to break the tie.

In the second phase of the study, Medication Review Service structural indicators were evaluated based on the structural indicators previously identified. It is important to emphasize that evaluations of the studies analyzed are self-evaluations. Therefore, to reduce possible biases and to provide an external validation of the results, each criterion was assessed by a pharmacist-investigator (G.A.S.J.) and a pharmacist-auditor (D.T.S.) external to the Medication Review service of the outpatient clinic analyzed. For each item, the responses of pharmacists-evaluators were grouped into three possible categories: yes (for items included in the service), no (for items not included) and not applicable (when the criterion did not suit local realities). The degree of agreement of these responses was also calculated by the *Kappa* index. All data collected were entered twice into an Excel spreadsheet and a descriptive statistical analysis was carried out.

This study was approved by the Research Ethics Committee of the University Hospital, Federal University of Sergipe (Brazil), under registration CAAE number 11735412.5.0000.5546. The pharmacists, physicians, Medical and Pharmacy students signed The Informed Consent (TCLE).

## **RESULTS**

### **Structural indicators for the Medication Review service**

In this study, only structural indicators to assess the Medication Review service were considered, although both guidelines also contained items for processes, which still need to be analyzed. Therefore, among the 77 items recommended by the ASHP (1999), only 14 refer to structural indicators. A clinical pharmacy service must satisfy the criteria highlighted in the guideline to reach the minimum standard. These are divided into four main categories: (I) leadership and management practice; (II)

pharmacotherapy and pharmaceutical care; (III) control and distribution of medicines; (IV) installations, equipment, and other resources. The guideline also points out that although these requirements may vary from place to place depending on the patients' needs, the criteria are strongly associated with the outcomes of the services provided to the patients and neglecting them may compromise service quality.

Similarly, in “*Guidelines for pharmacists providing Home Medicines Review (HMR) services*” (Pharmaceutical Society of Australia, 2011), only two items assess the structure of the service and were applied in this study. This guideline also covers the fundamental rules governing most types of Medication Review services existing in that country. Moreover, it also recommends that pharmacists familiarize themselves with other professional guidelines. Therefore, Medication Review practice must satisfy the 30 criteria recommended by the Pharmaceutical Society of Australia (2011), which are described in the guideline.

The degree of agreement between the two evaluators referring to all structural indicators was moderate ( $k=0.522$ ). However, after consensus on divergent items was reached, the index was excellent ( $k=0.894$ ). The structural indicators that were defined are described in Table 1.

**Table 1. Structural indicators for clinical pharmacy services**

Structural indicators	Reference
<b>PHYSICAL AREAS</b>	
Private area: private area to evaluate and guide the patient, to enable the assessment of his/her knowledge, understanding, and adherence to the prescribed pharmacotherapy and follow-up care plans. The space should accommodate the pharmacist, the patient, and when appropriate, family members or caregivers	(Aguiar et al., 2013; American Society of Health-System Pharmacists, 1999; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005)
Administrative area: area for administrative activities, meetings, and training	(American Society of Health-System Pharmacists, 1999)
Furniture (wardrobe, desk, and chair): furniture	Aguiar et al., 2013; Lyra Jr.,

---

suitable for providing care with patient seating and cabinets to store materials and documentation.

Internet: internet access available to the pharmacist. (Aguiar et al., 2013; Correr et al., 2004; Lyra Jr., 2005)

### **HUMAN RESOURCES**

Trained pharmacists: pharmacists with the necessary knowledge and skills to conduct Medication Review (Aguiar et al., 2013; American Society of Health-System Pharmacists, 1999; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005)

Trained staff: auxiliary staff trained to fulfill their responsibilities and work with pharmacists in Medication Review services (Aguiar et al., 2013; American Society of Health-System Pharmacists, 1999; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005)

Years to graduate in Pharmacy: time (in years) for the pharmacist to graduate. (Aguiar et al., 2013; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005)

Years of experience in clinical pharmaceutical services: time (in years) the pharmacist has worked in services such as clinical pharmacy, pharmaceutical care, Medication Review, or follow-up. (Aguiar et al., 2013; Correr et al., 2004; Lyra Jr., 2005)

Highest degree of the pharmacist (PharmD, MSc, PhD, or post-doctorate): previous participation of the pharmacist in graduate courses. (Aguiar et al., 2013; Correr et al., 2004; Lyra Jr., 2005)

Level of knowledge of foreign languages: the pharmacist should have at least basic knowledge of other foreign languages. (Aguiar et al., 2013; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005)

---

---

Pharmacist coordinator/Technical manager: the service should have a legally qualified and professionally competent pharmacist coordinator. The pharmacist technician in charge should know or have management experience or ambulatory care practice.	(American Society of Health-System Pharmacists, 1999; Silva, 2003)
Computer knowledge: experience in computer tools and internet resources used in the Medication Review service.	(França-Filho et al., 2008; Lyra Jr., 2005)
Pharmacist license: all pharmacists must have a license provided by their professional association to practice their occupation.	(American Society of Health-System Pharmacists, 1999; Pharmaceutical Society of Australia, 2011; Silva, 2003)
Working conditions of the staff: working conditions and remuneration in accordance with labor laws.	(Silva, 2003)
Certified technicians: all technicians must have the certification to practice their occupation in pharmaceutical services.	(American Society of Health-System Pharmacists, 1999)

### **MATERIAL RESOURCES**

Computer equipment (hardware): equipment, such as computers and printers, should be available to be used whenever necessary in the Medication Review service.	(Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005; Rios et al., 2013)
Information system: computerized system to archive the patients' information, drug therapy profile, and care plans.	(American Society of Health-System Pharmacists, 1999)
Medical devices: availability of medical devices that can be used in Medication Review, such as sphygmomanometer, stethoscope, thermometer, glucometer, and others.	(Aguiar et al., 2013; Rios et al., 2013; Silva, 2003)
Consumable materials: the office supplies used, such as paper, pen, among others, should be	(Lyra Jr., 2005; Rios et al., 2013; Silva, 2003)

---

---

available in a sufficient amount to meet the requirement of the service.

Available sources of information (primary, secondary, and tertiary): should include scientific and professional journals and latest editions of textbooks.

(Aguilar et al., 2013; American Society of Health-System Pharmacists, 1999; Correr et al., 2004; França-Filho et al., 2008; Lyra Jr., 2005; Rios et al., 2013; Silva, 2003)

Drug therapy form: the service should keep an updated form with the medicines approved by the medical staff.

(American Society of Health-System Pharmacists, 1999)

### **DOCUMENTATION**

Mission: the service should have a written mission that reflects patient care and the responsibilities of the service.

(American Society of Health-System Pharmacists, 1999)

Standards and technical procedures: a manual with all rules and procedures that govern outpatient pharmacy care (administrative, operational, and clinical) should be available and regularly updated.

(American Society of Health-System Pharmacists, 1999; Silva, 2003)

Laws and regulations: the pharmacist should maintain written or computerized documentation regarding law and recommendations compliance (local, state, and federal) applied to pharmaceutical services in outpatient clinics.

(American Society of Health-System Pharmacists, 1999; Silva, 2003)

Record of patients' clinical information: patients' clinical information should be recorded and stored in a secure location with restricted access.

(Silva, 2003)

Work schedules: work schedules, procedures, and staff assignments should exist to ensure safety, pharmaceutical, and patient care.

(American Society of Health-System Pharmacists, 1999)

Description of roles and functions:

(American Society of Health-

---

responsibilities and competencies of System Pharmacists, 1999)  
pharmacists and staff should be clearly defined  
and written.

## **FUNDING**

Funding for the service (Aguiar et al., 2013)

---

### **Evaluation of the Medication Review service of a school-based outpatient clinic**

The evaluation of structural indicators of the Medication Review service was carried out in the second phase of the study, for which the degree of agreement between pharmacist-investigator and pharmacist-auditor, who was external to the service, was excellent ( $k=0.889$ ).

Regarding the evaluation of physical facilities, the outpatient clinic had an air-conditioned private room of approximately 12m<sup>2</sup> for pharmacy care that was not exclusive to the Medication Review service. The furniture of the room was similar to other outpatient clinics and included a table, chairs, a stretcher, and a cabinet. The material resources used were purchased with the pharmacist's own funds and funds from other research projects. Therefore, sources of primary, secondary, and tertiary information were rendered available to pharmacists, physicians, patients, Medical students, and Pharmacy students. Importantly, despite the lack of computers with internet access, the service had a tablet with internet access that allowed quick searches of evidence-based medicine content. Consumables were acquired over the period of care provision and it was not necessary to purchase medical devices (sphygmomanometer, stethoscope, glucometer, thermometer, etc.).

With regard to human resources, although not from the University Hospital under study, four pharmacists (one coordinator and three caregivers) and eight Pharmacy students (four trainees, two undergraduate students, and two volunteer students) formed the Medication Review service. All twelve had a workload of 20 hours per week and most of them were women (58.33%;  $n=7$ ).

The average age of the pharmacists was  $30.75 \pm 8.73$  years and 50% were men ( $n=2$ ). With regard to training, two pharmacists were MSc students, one was a PhD student, and one was a post-doc; the average time for graduation was  $8 \pm 8.04$



years and the average time of direct patient care experience was  $5.5 \pm 4.36$  years. All pharmacists had advanced knowledge of English.

The average age of the Pharmacy students was  $22.25 \pm 1.28$  years and the majority were women (62.5%; n=5) and attended the eighth semester of the Pharmacy course. Half of these students had intermediate English levels, three spoke basic English, and only one was fluent. Most students (75%; n=6) had never cared for patients in clinical care-focused services. Therefore, before starting service attendance, all students participated in a training course organized and promoted by pharmacists, which consisted of 20 hours of theoretical training (four hours of service simulation, four hours of searching sources of information, four hours of legal aspects on medical prescription, four hours of documentation, and four hours of pharmaceutical diagnosis) and 32 hours of practical training (direct practice observation and supervised service, which were monitored by the pharmacists in charge). The entire staff (pharmacists and Pharmacy students) had advanced computer knowledge.

As computers were not available, the documents were manually prepared, using forms adapted by the authors of the study (Cipolle et al., 2012). Regarding service documentation, care flowcharts (standards and technical procedures) were printed out and rendered available to all the staff members.

As for financial resources and since three pharmacists and two undergraduate students were participating in research projects, they were funded by local and national agencies. Moreover, it is important to notice that Medication Review was paid according to procedures listed in the table of the Brazilian Unified Health System (SUS) and according to the consultation category of senior level professionals for specialized care. However, the resources obtained were curiously not used to directly support the service.

## **DISCUSSION**

Implantation of quality clinical pharmacy services, initially, requires the development of research on structures to delineate the profile of existing conditions that translate into changes necessary for their viability (Correr et al., 2004; França-

Filho et al., 2008 ; Lyra Jr., 2005; Silva, 2003). As proposed by Donabedian (1980), structural indicators should be initially used to evaluate and implement health services as these are essential for subsequent phases, including processes and outcomes.

In this study, we observed that several international indicators found were similar to national indicators. Therefore, the international guidelines selected to evaluate structural indicators of Medication Review service complemented indicators of selected national studies. This similarity can be explained by a new global tendency in pharmacy wherein the pharmacists' activities are not only focused on medicines but also on providing care (Nkansah et al., 2010). Therefore, indicators could be used to evaluate these services.

The adaptation of several indicators assessed in this study to meet the local reality is recommended in the literature (American Society of Health-System Pharmacists, 1999). For instance, the U.S. guideline "*Minimum Standard for Pharmaceutical Services in Ambulatory Care*" recommends that pharmacists evaluate and adapt these rules to meet the requirements of each practice that is being carried out (American Society of Health-System Pharmacists, 1999). Moreover, the literature shows that protocols and guidelines developed by professional societies should be used as parameters for quality improvement (Woolf et al., 1999). Therefore, the adoption of international standards and national indicators may have been crucial for structuring the service. According to Donabedian (1980), it is important to assess structural measures, because they influence processes and results.

As for human resources, the qualification of the pharmacists and their prior experience in patient care were important for the implementation of this service. In countries such as Australia and Finland, in addition to experience, pharmacists undergo accreditation processes and participate in periodic updates while conducting Medication Review services (American Society of Health-System Pharmacists, 1999; Leikola, 2012). Although no accreditation processes have been established so far in Brazil, Smith (2009) emphasizes that the clinical experience of pharmacists may positively influence patients' health outcomes. This allows patients to take care of themselves and contributes, together with other health professionals, to ensure the appropriate, cost-effective, safe, and convenient use of medication. Moreover, the

implementation of indicators in Brazil may contribute to the development of future accreditation processes in these clinical pharmacy services.

With regard to human resources, the literature emphasizes the importance of training programs and effective supervision, which aims to increase the knowledge and practice of pharmacists and students, thus improving the care provided to the community (Minh et al., 2013). In this study, the fact that all pharmacists were involved in teaching and research may have facilitated the training process of Pharmacy students who were interested in developing clinical services, which favored the implementation of the service and the formation of a practice environment.

As recommended by the ASHP, in Medication Review services pharmacists and Pharmacy students must go through a selection process, and theoretical and practical training to improve the knowledge and skills required developing patient care activities (American Society of Health-System Pharmacists, 1999). In this study, the selected students were trained by pharmacists of the service and invited according to relevant topics for the Medication Review. It is important to emphasize that due to insufficient knowledge and skills offered by the curricula of Pharmacy students, as established by Resolution number 02 (2002), of National Education Council/Higher Education Council (CNE/CES), of 2002, complementary training on ambulatory care services is required.

In addition to human resources, infrastructure is an important component to confer quality to healthcare services. In this study, the infrastructure that was used was in agreement with the national and international literature, which recommends the existence of a private or semiprivate space with appropriate furniture, able to promote the safe and efficient workflow of pharmacists, academics, patients, and/or caregivers while attended at the Medication Review service (Aguiar et al., 2013; França-Filho et al., 2008; Lyra Jr., 2005; Pharmaceutical Society of Australia, 2011). In the practice of the Medication Review service, the existence of a private area for pharmaceutical care contributed to the creation of therapeutic relationships between pharmacists, Pharmacy students, and patients. To support this notion, the study of Pringle et al. (2011) demonstrated that the patient achieves good health outcomes when a therapeutic bond is formed with the pharmacist. However, França-

Filho et al. (2008) found that only 11.4% of pharmacies providing pharmaceutical services in the State of Santa Catarina (Brazil) had a private or semiprivate area.

In the Medication Review service that was studied, clinical pharmacy services was given in the same area where medical examinations were performed and immediately after they occurred to avoid further displacement to the hospital, especially for patients coming from other cities or states. Moreover, when problems are detected when reviewing a patient's medication, pharmacists and Pharmacy students may intervene immediately with doctors to optimize the pharmacotherapy prescribed. However, in this service the therapeutic relationship was compromised as the consultations were short and did not allow detailed interviewing of patients.

In Australia and Finland, Medication Review that starts in the community pharmacy or in the doctor's office may be complemented at home, thus facilitating the therapeutic pharmacist-patient relationship (Leikola, 2012; Pharmaceutical Society of Australia, 2011). It is important to emphasize some benefits of homecare, such as identification of discrepancies with medicines dispensed in community pharmacies, storage and administration of pharmacotherapy, and lifestyles that influence the use of medications (Hsia et al., 1997; Leikola, 2012; Yang et al., 2001). According to these authors, the patients' home environment is more comfortable and suitable for the creation of a therapeutic relationship with the patient. In the future, the extension of Medication Review services to domiciliary care, integrated with other hospital clinical services such as Pharmacy residency, may represent an effective strategy to improve patient care.

As for material resources, consultation of information sources about medications was not compromised in this study by the absence of computers connected to internet. In this study, updated textbooks, scientific papers, standards, and relevant legislation(laws, resolutions, ordinances, etc.), booklets, and materials developed by the authors were rendered available, in addition to mobile internet resources that were available by tablet, which enabled efficient database consultations as recommended by the literature (França-Filho et al., 2008; Wazaify et al., 2004; Zehnder et al., 2004).

To provide this, pharmacists and Pharmacy students working in the service had unlimited access to medical sources of information, which required specific training and knowledge of other languages. Therefore, the results obtained were better than

those found in other national and international studies (Correr et al., 2004; Rodríguez et al., 2000). Although the literature suggests that clinical pharmacy services should have clinical devices (sphygmomanometer, glucometer, thermometer, etc.), they were not necessary in this study, since clinical and laboratory examinations were performed by physicians or clinical laboratories, and the results were rendered available to the entire staff in the records (Rios et al., 2013; Silva, 2003). Furthermore, documentation is a structural indicator for services.

Zierler-Brown et al. (2007) state that documentation should be clear, concise, readable, free of judgments, systematized, centered on the patient, and ensure confidentiality. Therefore, the preparation of structured forms to document the care provided in this study, the training of the team in documentation and service simulation, combined with patients' availability and their clinical information (medical records, clinical and laboratory examinations, and medical reports), led to pharmacists' records meeting the literature recommendations. Moreover, Mackinnon and Mackinnon (2008) argue that documentation is necessary for the communication between pharmacists and other health care professionals, which stresses their importance in decision-making and patients' clinical outcomes. Besides, the documentation used by the service should undergo continuous updates to satisfy new requirements presented by each patient.

Regarding funding indicators, studies suggest that in other countries, health providers pay for patient care services and support clinical pharmacy services (Consejería de Sanidad y Consumo, 2006; Kuo et al., 2004; Leikola, 2012). Although the Medication Review service charges the consultation according to the Brazilian Unified Health System (SUS) Table in an innovative way, the resources obtained are not directly reverted to support the service. Moreover, service functioning depends on the fellowships of undergraduate and graduate students. Then, it is necessary to implement measures that aim to support the service, through the recruitment of pharmacists, investment in specific structures, and integration with other services, such as the residency.

## **CONCLUSION**

This study emphasized structural indicators required to evaluate the Medication Review service. Additionally, the developed structure satisfied the majority of the indicators proposed and may contribute to the establishment of structural standards for similar services. In a complementary form, it is expected that further studies should focus on work processes of Medication Review at ambulatory levels. It will thus be possible to implement structured Medication Review services with well-defined workflows and positive results for patients and health professional teams.

## **ACKNOWLEDGMENTS**

This research was supported by the Sergipe State Research and Innovation Support Foundation (FAPITEC/SE), National Council for Scientific and Technological Development (CNPq) and Coordination for the Improvement of Higher Education Personnel (CAPES).

## REFERENCES

Adami, N.P., Maranhão, A.M.S.A., 1995. Qualidade dos serviços de saúde: conceitos e métodos avaliativos. *Acta Paulista de Enfermagem* 8(4), 47-55.

Aguiar, P.M., Balisa-Rocha, B.J., Lyra Jr, D.P., 2013. Implantação do serviço de Atenção Farmacêutica na Farmácia Popular do Brasil: um estudo piloto. *Revista de Ciências Farmacêuticas Básica e Aplicada* 34(3), 401-410.

American Society of Health-System Pharmacists, 1999. ASHP guidelines: minimum standard for pharmaceutical services in ambulatory care. *American Journal of Health-System Pharmacy* 56, 1744-1753.

Bruchet, N., Loewen, P., 2011. Improving the quality of clinical pharmacy services: a process to identify and capture high-value "Quality Actions". *Canadian Journal of Hospital Pharmacy* 64(1), 42-47.

Carayon, P., Wetterneck, T.B., Rivera-Rodriguez, A.J., Hundt, A.S., Hoonakker, P., Holden, R., Gurses, A.P., 2014. Human factors systems approach to healthcare quality and patient safety. *Applied Ergonomics* 45(1), 14-25, <http://dx.doi.org/10.1016/j.apergo.2013.04.023>.

Cipolle, R.J., Strand L.M., Morley, P.C., 2012. *Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management*. McGraw-Hill Medical, Minneapolis.

Correr, C.J., Rossignoli, P., Souza, R.A.P., Pontarolo, R., 2004. Perfil de los farmacéuticos e indicadores de estructura y proceso en farmacias de Curitiba – Brasil. *Seguimiento Farmacoterapéutico* 2(1), 37-45.

Dirección General de Farmacia y Productos Sanitarios, 2006. Programa de Atenciónal Mayor polimedicado para la mejora en la utilización de los medicamentos. Consejería de Sanidad y Consumo, Madrid.

Donabedian, A., 1966. Evaluating the quality of medical care. *Milbank Memorial Fund Quarterly* 44, 166-206, <http://dx.doi.org/10.1111/j.1468-0009.2005.00397.x>.

Donabedian, A., 1978. The quality of medical care. *Science* 200(4344), 856-864.

Donabedian, A., 1980. The definition of quality and approaches to its assessment. Health Administration Press, Ann Arbor.

Donabedian, A., 1988. The quality of care. How can it be assessed? *Journal of the American Medical Association* 260(12), 1743-1748.

Doucette, W.R., Witry, M.J., Farris, K.B., McDonough, R.P., 2009. Community pharmacist-provided extended diabetes care. *Annals of Pharmacotherapy* 43(5), 882-889, <http://dx.doi.org/10.1345/aph.1L605>.

El-Ibiar, S.Y., Cheng, C., Alldredge, B., 2008. Potential roles for pharmacists in pharmacogenetics. *Journal of American Pharmacists Association* 48(2), e21-29, <http://dx.doi.org/10.1331/JAPhA.2008.07050>.

Farris, K.B., Kirking, D.M., 1993. Assessing the quality of pharmaceutical care. II. Application of concepts of quality assessment from medical care. *Annals of Pharmacotherapy* 27(2), 215-223.

França-Filho, J.B., Correr, C.J., Rossignoli, P., Melchior, A.C., Fernández-Llimós, F., Pontarolo, R., 2008. Perfil dos farmacêuticos e farmácias em Santa Catarina: indicadores de estrutura e processo. *Brazilian Journal of Pharmaceutical Sciences* 44(1), 105-113.

Hatah, E., Braund, R., Tordoff, J., Duffull, S.B., 2014. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. *British Journal of Clinical Pharmacology* 77(1), 102–115.



Hsia, D.E., Rubenstein, L.Z., Choy, G.S., 1997. The benefits of in-home pharmacy evaluation for older persons. *Journal of the American Geriatrics Society* 45, 211-214.

Kuo, G.M, Buckley, T.E, Fitzsimmons, D.S., Steinbauer, J.R., 2004. Collaborative drug therapy management services and reimbursement in a family medicine clinic. *American Journal of Health-System Pharmacy* 61(4), 343-354.

Leikola, S., 2012. Development and application of comprehensive medication review procedure to community-dwelling elderly. Doctoral Dissertation, University of Helsinki, Helsinki.

Lyra Jr, D.P., 2005 Impacto de um programa de Atenção Farmacêutica nos resultados clínicos e humanísticos de um grupo de idosos, assistidos na unidade Básica de Saúde Dr. Ítalo Baruffi, Ribeirão Preto (SP). Doctoral Dissertation, University of São Paulo, Ribeirão Preto.

Mackinnon, G.E., Mackinnon, N., 2008. Documentation of pharmacy service. In: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds), *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill, New York, pp. 34-45.

Mainz, J., 2003. Defining and classifying clinical indicators for quality improvement. *International Journal for Quality in Health Care* 15(6), 523-530, <http://dx.doi.org/10.1093/intqhc/mzg081>.

McBane, S., Trewet, C.B., Havican, S.M., Kiser, K., Klingel, C., Riche, D.M., Sease, J.M., Nau, D.P., Zillich A.J., 2011. Tenets for developing quality measures for ambulatory clinical pharmacy services. *Pharmacotherapy* 31(7), 115-134, <http://dx.doi.org/10.1592/phco.31.7.723>.

Minh, P.D., Huong, D.T., Byrkit, R., Murray M., 2013. Strengthening pharmacy practice in Vietnam: findings of a training intervention study. *Tropical Medicine and International Health* 18(4), 426-434, <http://dx.doi.org/10.1111/tmi.12062>.

Murray, M.D., Young, J., Hoke, S., Tu, W., Weiner, M., Morrow D., 2007. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. *Annals of Internal Medicine* 146(10), 714-725.

Nau, D.P., 2009. Measuring pharmacy quality. *Journal of American Pharmacists Association* 49, 212-229, <http://dx.doi.org/10.1331/JAPhA.2009.09019>.

Nkansah, N., Mostovetsky, O., Yu, C., Chheng, T., Beney, J., Bond, C.M., Lisa, B., 2010. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. *Cochrane Database of Systematic Reviews*, 7, <http://dx.doi.org/10.1002/14651858.CD000336.pub2>.

Pharmaceutical Society of Australia, 2011. Guidelines for pharmacists providing Home Medicines Review (HMR) services. PSA, Canberra.

Planas, L.G., Crosby, K.M., Mitchell, K.D., Farmer, K.C., 2009. Evaluation of a hypertension medication therapy management program in patients with diabetes. *Journal of American Pharmacists Association* 49(2), 164-170, <http://dx.doi.org/10.1331/JAPhA.2009.08164>

Pringle, J., Melczak, M., Aldridge, A., Snyder, M., Smith, R., 2011. Medication adherence and its relationship to the therapeutic alliance: results from an innovative pilot study within a community pharmacy MTM practice. *Innovations in pharmacy* 2(1), 1-16.

Resolution number 02 of CNE/CES of February 19, 2002. Institui Diretrizes Curriculares Nacionais do Curso de Graduação em Farmácia. Conselho Nacional de Educação, Câmara de Educação Superior. Diário Oficial da União, Ministério da Educação, Brasília.

Rios, M.C., Cruz, A.D., Balisa-Rocha, B.J., Brito G.C., Rios, S.S., Lyra Jr., 2013. Estruturação de farmácias comunitárias para implementação dos serviços farmacêuticos. *Revista Brasileira de Farmácia* 94(1), 66-71.

Roberts, A.S., Benrimoj, S.I., Chen, T.F., Williams, K.A., Aslani P., 2008. Practice change in community pharmacy: quantification of facilitators. *Annals of Pharmacotherapy* 42(6), 861-868, <http://dx.doi.org/10.1345/aph.1K617>.

Rodríguez, N.F.A., Riestra R.G., Hermida, M.T.O., Somoza F.F.I., 2000. Perfil de los integrantes de los grupos de trabajo Del Colegio de Farmacéuticos de Pontevedra. *Pharmaceutical Care España* 2, 20-27.

Shaw, J., Seal, R., Pilling, M., 2003. Task force on medicines partnership and the national collaborative medicines management services programme. Room for review - a guide to medication review: the agenda for patients, practitioners and managers. Pharmaceutical Press, Wallingford.

Silva, R. R., 2003. Acreditação de farmácias: a construção de um modelo. Doctoral Dissertation, University of São Paulo, São Paulo.

Smith, M., 2009. Pharmacists' role in improving diabetes medication management. *Journal of Diabetes Science and Technology* 3(1), 175-179.

Wazaify, M., Maani, M., Ball, D., 2009. Drug information resources at community pharmacies in Amman, Jordan. *International Journal of Pharmacy Practice* 17(3), 151-155.

Woolf, S.H., Grol, R., Hutchinson A., Eccles, M., Grimshaw, J., 1999. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. *British Medical Journal* 318(7182), 527-530, <http://dx.doi.org/10.1136/bmj.318.7182.527>.

World Health Organization, 1994. The Role of the Pharmacist in the Health Care System[Online]. WHO, New Delhi, December 16, 1988 and Tokyo, September 3, 1993. URL: <http://apps.who.int/medicinedocs/en/d/Jh2995e/> (accessed 14.04.13).

World Health Organization, 1998. The role of the pharmacist in self-care and self-medication. Report of the 4<sup>th</sup> Consultative Group on the Role of the Pharmacist. WHO, Hague.

Yang, Z., Peterson, R.T., Huang, L., 2011. Taking the pulse of Internet pharmacies. *Marketing Health Services* 21(2), 4-10.

Zehnder, S., Beutler, M., Bruppacher, R., Ehrenhöfer, T., Hersberger K., 2004. Needs and use of drug information sources in community pharmacies: a questionnaire based survey in German-speaking Switzerland. *Pharmacy World and Science* 26(4), 197-202.

Zierler-Brown, S., Brown, T.R., Chen, D., Blackburn, R.W., 2007. Clinical documentation for patient care: models, concepts, and liability considerations for pharmacists. *American Journal of Health-System Pharmacy* 64(17), 1851-1858.

## **RESEARCH HIGHLIGHTS**

- We gathered 28 structure indicators that were divided into five categories.
- Categories: physical areas, documentation, funding, human resources and material.
- Several international indicators found were similar to national indicators.
- The Medication Review Service analyzed attended most indicators gathered.
- This study may contribute to the establishment of structural standards.

## **AUTHOR DECLARATION**

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from lepfs.ufs@gmail.com.

# HEALTH & PLACE

## ***Guide for authors***

### **INTRODUCTION**

The journal is an interdisciplinary journal dedicated to the study of all aspects of health and health care in which place or location matters.

Recent years have seen closer links evolving between medical geography, medical sociology, health policy, public health and epidemiology. The journal reflects these convergences, which emphasise differences in health and health care between places, the experience of health and care in specific places, the development of health care for places, and the methodologies and theories underpinning the study of these issues.

The journal brings together international contributors from geography, sociology, social policy and public health. It offers readers comparative perspectives on the difference that place makes to the incidence of ill-health, the structuring of health-related behaviour, the provision and use of health services, and the development of health policy.

At a time when health matters are the subject of ever-increasing attention, *Health & Place* provides accessible and readable papers summarizing developments and reporting the latest research findings.

### **Types of paper**

Articles should normally be 4000-6000 words long, although articles longer than 6000 words will be accepted on an occasional basis, if the topic demands this length of treatment. Authors are responsible for ensuring that all manuscripts (whether original or revised) are accurately typed before final submission.

Manuscripts will be returned to the author with a set of instructions if they are not submitted according to our style.

The Short Reports section allows authors to submit material which might not be appropriate for full-length articles but is worthy of publication. It may report work-in-progress or elements of larger projects (1000-2000 words).

The viewpoints section exists for the expression of opinion and as a forum for debate (1000-2000 words).

Review papers may provide scholarly assessments of new policies or practices, or academic overviews of new areas of study (5000-6000 words).

### **Special issue policy**

Our policy on special issues is that we will not do complete special issues, rather we will consider special sections of 4-10 papers. Specials need to be proposed to the Editor in Chief and will be evaluated by Assistant Editors and one or more Board Members and/or external advisors. Proposals should normally include abstracts and must include a clearly argued case for the special. Exceptionally we will consider specials based around a call-for-papers. Evaluation will focus on the coherence, topicality and market for the special. We expect specials to pursue an agenda and to be introduced by an agenda-setting paper, which could take the form of a guest editorial. All papers in specials, including the lead paper should be submitted in the normal way and will undergo normal peer review. We anticipate one special per year.

### **Contact details for submission**

*Health & Place* has an online submission system with the aim of improving our editorial procedure for authors, reviewers and the editor. The website address is: <http://ees.elsevier.com/jhap>.

If this is your first time using the system you will need to go to the above page and register as a new author by clicking the 'Register' link. Once registered you may then submit your paper by clicking 'Submit New Manuscript' and following the



instructions. All correspondence between the editor and authors will be performed by e-mail and paper copies will not be required at the original submission stage.

### ***Review Policy***

Please note that the journal has adopted a double blind reviewing policy, so authors should use separate pages for all identifying information (name, affiliation etc.). Replace all references to the author in the main paper with "Author, 2003", "Author et al, 2006", etc. In the reference list, use the format "Author 2003 [details removed for peer review]". **Papers that have not had all such features removed will be returned without review to the author for alteration.** Reviewer's names will not be made available to authors under any circumstances.

### **BEFORE YOU BEGIN**

#### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

#### **Conflict of interest**

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

#### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

## **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

## Copyright

This journal offers authors a choice in publishing their research: Open access and Subscription.

### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

### ***Retained author rights***

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.

Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY):** lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access. Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee for this journal is **\$1800**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-out that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of

publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### **Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

### ***Figures and tables embedded in text***

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

## **REVISED SUBMISSIONS**

### ***Use of word processing software***

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## Article structure

### Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### Optimizing the title and abstract of an article for your audience

In order to increase the exposure of your article, we suggest the following:

- The title of your article must be clear and descriptive, using keywords that are relevant to the subject area, and would most likely be used in an online search.

- The abstract must also contain keywords and common phrases for the subject area, perhaps using wording from the title. These carefully chosen keywords



and phrases can also be emphasised in the text, however please do this with caution as some search engines can reject overly repetitive webpages.

## **Abstract**

A concise and factual abstract of about 100 words is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

## **Highlights**

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

## **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

## **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may

be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

## **Artwork**

### ***Electronic artwork***

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available on our website: <http://www.elsevier.com/artworkinstructions>.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

***Color artwork***

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

***Figure captions***

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the

illustrations themselves to a minimum but explain all symbols and abbreviations used.

## **Tables**

Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

## **References**

### ***Citation in text***

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### ***Reference links***

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

### ***Web references***

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### ***References in a special issue***

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### ***Reference management software***

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to word processing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

### ***Reference formatting***

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

## Reference Style

For *Health & Place* the Harvard system is to be used: authors' names (no initials) and dates (and specific pages, only in the case of quotations) are given in the main body of the text, e.g. (Phillips, 1990, p, 40). References are listed alphabetically at the end of the paper, double spaced and conform to current journal style:

**For journals:** Macintyre, S., MacIver, S., Sooman, A., 1993. Area, class and health: should we be focusing on places or people? *Journal of Social Policy* 22, 213-234.

**For books:** Jones, K., Moon, G., 1987. *Health, Disease and Society*. RKP, London.

**For Chapters of edited Books:** Laws, G., Dear, M., 1988. Coping in the community: a review of factors and influencing the lives of deinstitutionalized ex-psychiatric patients. In: Smith, C., Giggs, J. (Eds), *Location and Stigma*. Unwin Hyman, London, pp. 83-102.

**Other publications:** Where there is doubt include bibliographical details.

## Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize

the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

## **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

## **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

## **Google Maps and KML files**

KML (Keyhole Markup Language) files (optional): You can enrich your online articles by providing KML or KMZ files which will be visualized using Google maps. The KML or KMZ files can be uploaded in our online submission system. KML is an XML schema for expressing geographic annotation and visualization within Internet-based Earth browsers. Elsevier will generate Google Maps from the submitted KML files and include these in the article when published online. Submitted KML files will also be available for downloading from your online article on ScienceDirect. For more information see <http://www.elsevier.com/googlemaps>.

## **Checklist**

- Have you told readers, at the outset, what they might gain by reading your paper?
- Have you made the aim of your work clear?
- Have you explained the significance of your contribution?
- Have you set your work in the appropriate context by giving sufficient background (including a complete set of relevant references) to your work?
- Have you addressed the question of practicality and usefulness?
- Have you identified future developments that may result from your work?
- Have you structured your papers in a clear and logical fashion?
- Have you provided an abstract and keywords?

## **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:



- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa

versa

- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <http://support.elsevier.com>.

## **AFTER ACCEPTANCE**

### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an

article in the journal *Physics Letters B*:  
<http://dx.doi.org/10.1016/j.physletb.2010.09.059>.

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail (the PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use). For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's

WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

## **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.